Success Stories: A Principal Scientist in the Field of Oncology Secures NIW and EB1A Approvals Miraculously on the Same Day with our Continuous Support
Client’s Testimonial:
“Thank you so much for your help!”
On October 1st, we received another EB2-NIW (National Interest Waiver) and EB-1A (Alien of Extraordinary Ability) approval for a Principal Scientist in the Field of Oncology (Approval Notice).
General Field: Oncology
Position at the Time of Case Filing: Principal Scientist
Country of Origin: Hong Kong
State of Residence at the Time of Filing: Massachusetts
Approval Notice Date: October 1st, 2021 (NIW & EB-1A)
Processing Time: 9 months, 22 days (NIW) and 11 months, 20 days (EB-1A)
Case Summary:
Initially, our client, a principal scientist with a Ph.D. in molecular oncology from Hong Kong, approached North America Immigration Law Group to help her in filing an I-140 petition under the national interest waiver visa category and within two months she decided to retain our services for another I-140 petition documentation under the alien of extraordinary ability visa category. Despite two different petition categories, we have first-hand knowledge of how to exactly file these two petitions consecutively to acquire the desired result for our clients.
Therefore, both EB-2 NIW (National Interest Waiver) and EB1-A (Alien of Extraordinary Ability) petition approvals were granted on the same day to our client. When we commenced with the attorney-client relationship agreement, the first and foremost task for our team was to evaluate her provided credentials to determine her NIW and EB1A victory respectively. We were certain that we would be able to lead her to obtain the approvals successfully.
After analyzing her background, paperwork, and the associated evidence, we were pretty much confident that they were inevitable to persuade USCIS, thus, we incorporated the following in her respective petition packets:
- The 13 peer-reviewed journal articles she published in no fewer than 6 highly ranked peer-reviewed journals in the field of oncology.
- A great record of 515 citations was acquired from her published work, proving that many other experts have utilized her findings and strategies with favorable results.
- Cited by researchers in at least 44 countries.
- She has also been invited to review and evaluate the work of her peers no fewer than 29 times, serving as major evidence of her superiority in the field.
In addition, considering her other results provide improved, tailored treatment strategies for lung cancer patients, demonstrating the crucial nature of her studies for improving survival outcomes of lung cancer patients, corroborated further by four recommendation letters obtained from her fellow experts in the field. One of the letters had the below-mentioned statement.
“The importance of identifying new approaches to regulate lung cancer is crucial to curbing the impact of the disease. Lung cancer is the second most common cancer worldwide and has been among the most common cancers overall for several decades. [Client’s] research advances the development of new therapeutic drug targets for patients with lung cancer. Her work has revealed the impact of integrating molecular profiling data to obtain biological insights into formerly uncharacterized lung cancer prognostic biomarkers… Therefore, the importance of her research for advancing novel therapeutics to overcome one of the most common causes of death worldwide must be highlighted.”
Once again, we are delighted that our team was very well successful in persuading USCIS of our client’s research which is relevant to identifying new druggable targets to treat cancer patients. Thus, she achieved both the approvals on the same day, and we would generously like to thank her for trusting our law firm for the I-140 petitions and wish her well in her future endeavors.